Vimarsana.com

Latest Breaking News On - Kevin charles gorman - Page 1 : vimarsana.com

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Expected to Post Q2 2024 Earnings of $1.11 Per Share

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Expected to Post Q2 2024 Earnings of $1.11 Per Share
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United-states
Neurocrine-biosciences
Neurocrine-bioscience
William-blair
Kevin-charles-gorman
Davidw-boyer
First-horizon-advisors-inc
Commonwealth-equity-services
Nasdaq
Quadrant-capital-group
Securities-exchange-commission
Envestnet-portfolio-solutions-inc

Certuity LLC Invests $415,000 in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Certuity LLC purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the fourth quarter, HoldingsChannel reports. The fund purchased 3,150 shares of the company’s stock, valued at approximately $415,000. Several other institutional investors and hedge funds have also bought and sold shares of the stock. Headinvest LLC purchased a new stake […]

United-states
Neurocrine-biosciences
Kevin-charles-gorman
Eric-benevich
Nasdaq
Bluepath-capital-management
Fifth-third-bancorp
Wells-fargo-company
Third-bancorp
Barclays
Lindbrook-capital
Neurocrine-biosciences-inc

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $138.00 at BMO Capital Markets

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $138.00 at BMO Capital Markets
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-states
Los-angeles
California
Neurocrine-biosciences
Kevin-charles-gorman
Ingrid-delaet
Capital-partners
Jpmorgan-chase-co
Vanguard-group-inc
Goldman-sachs-group
Los-angeles-capital-management
Brown-advisory-inc

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Increased to $164.00 by Analysts at Canaccord Genuity Group

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its target price hoisted by research analysts at Canaccord Genuity Group from $154.00 to $164.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 17.29% from […]

United-states
Ingrid-delaet
Neurocrine-biosciences
Kevin-charles-gorman
Canaccord-genuity-group
Edgerock-capital
Barclays
Jpmorgan-chase-co
Neurocrine-biosciences-inc
Mather-group
Lindbrook-capital
Benjaminf-edwards-company-inc

Russell Investments Group Ltd. Decreases Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Russell Investments Group Ltd. Decreases Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-states
Neurocrine-biosciences
Kevin-charles-gorman
Matt-abernethy
Barclays
Capital-partners
Securities-exchange-commission
Charles-schwab-investment-management-inc
Cantor-fitzgerald
Citigroup
Neurocrine-biosciences-company-profile
Westfield-capital-management-co

New York State Common Retirement Fund Sells 29,456 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

New York State Common Retirement Fund lessened its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 12.1% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 214,396 shares of the company’s stock after selling 29,456 shares during the period. New York State Common […]

New-york
United-states
Neurocrine-biosciences
Eiry-roberts
Kevin-charles-gorman
Nasdaq
Citigroup
Wells-fargo-company
Metis-global-partners
Red-spruce-capital
Lindbrook-capital
York-state-common-retirement-fund

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Larson Financial Group LLC

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Larson Financial Group LLC
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United-states
Neurocrine-biosciences
Eric-benevich
Kevin-charles-gorman
Nasdaq
Securities-exchange-commission
Metis-global-partners
Neurocrine-biosciences-inc
Jpmorgan-chase-co
Needham-company
Exchange-commission
Red-spruce-capital

Jennison Associates LLC Increases Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Jennison Associates LLC Increases Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United-states
Neurocrine-biosciences
Eric-benevich
Kevin-charles-gorman
Nasdaq
Jennison-associates
Jpmorgan-chase-co
Metis-global-partners
Sunbelt-securities-inc
Lindbrook-capital
Needham-company
Neurocrine-biosciences-inc

Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap Up to $133.66

Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap Up to $133.66
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United-states
Kevin-charles-gorman
Eiry-roberts
Neurocrine-biosciences
Jpmorgan-chase-co
Edgerock-capital
Mather-group
Needham-company
Nasdaq
Wells-fargo-company
Neurocrine-biosciences-inc
Benjaminf-edwards-company-inc

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives $139.25 Consensus Target Price from Analysts

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives $139.25 Consensus Target Price from Analysts
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-states
Neurocrine-biosciences
Kevin-charles-gorman
Acadian-asset-management
Nasdaq
Neurocrine-biosciences-inc
Dimensional-fund-advisors
Hightower-advisors
Cantor-fitzgerald
Financial-services-group-inc
Barclays
Rice-hall-james-associates

vimarsana © 2020. All Rights Reserved.